<DOC>
	<DOCNO>NCT00385697</DOCNO>
	<brief_summary>The primary purpose protocol ass efficacy , tolerability , safety MGA031 administer accord 3 different MGA031 dosing regimens child adult recent-onset ( diagnosis within past 12 week ) type 1 diabetes mellitus . All regimen administer addition insulin standard care treatment . Efficacy define primarily capacity MGA031 markedly reduce typical insulin requirement maintain relatively normal blood sugar level . Other study involve study drug use name hOKT3γ1 ( Ala-Ala ) . MGA031 , humanize monoclonal antibody , name use hOKT3γ1 ( Ala-Ala ) produce MacroGenics , Inc . The United States Adopted Name ( USAN ) MGA031 teplizumab .</brief_summary>
	<brief_title>The Protégé Study - Clinical Trial MGA031 Children Adults With Recent-Onset Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>The Protégé Study - A Multinational Clinical Trial MGA031 Preserving Capability Produce Insulin , Reducing Insulin Usage Improving Blood Sugar Levels Children Adults With Recent-Onset Type 1 Diabetes Mellitus</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Subjects must meet following criterion : 1 . Enrollment ( Segment # 1 ) randomization ( Segment # 2 ) Study Day 0 within 12 week first visit physician symptom sign diabetes . Study Day 0 first day study drug dose . 2 . Diagnosis type 1 diabetes mellitus , accord American Diabetes Association ( ADA ) criteria 3 . Requirement injected insulin therapy 4 . Have detectable fasting stimulate Cpeptide level ( low limit detection assay ) 5 . One positive result test follow antibody : 1. isletcell autoantibody ( ICA512/IA2 ) , 2. glutamic acid decarboxylase autoantibody , 3. insulin autoantibody ( present first 2 week , beyond 2 week , insulin treatment ) 6 . Male female 7 . Subject must one follow age group : Age 1835 year Age 1217 year pending approval Data Monitoring Committee Age 811 year pending approval Data Monitoring Committee 8 . Body weight ≥ 36 kg Subjects must none following : 1 . Prior administration monoclonal antibody within 1 year enrollment randomization Study Day 0 could potentially prevent confound therapeutic response MGA031 2 . Participation type therapeutic drug vaccine clinical trial within 12 week enrollment randomization 3 . Any medical condition , opinion investigator , would interfere safe completion trial 4 . Pregnant lactating female 5 . Prior murine OKT®3 treatment time enrollment randomization 6 . Current plan therapy exenatide agent stimulate pancreatic beta cell regeneration insulin secretion 7 . Current plan therapy inhale insulin 8 . Uncompensated heart failure , fluid overload , myocardial infarction evidence ischemic heart disease , serious cardiac disease within 12 week enrollment randomization 9 . History epilepsy , cancer , cystic fibrosis , sickle cell anemia , neuropathy , peripheral vascular disease cerebrovascular disease 10 . Newly diagnose hypothyroidism ( currently treat , opinion investigator , treat ) active Graves ' disease 11 . Eczema , asthma severe atopic disease require treatment within 12 week enrollment randomization 12 . Evidence active infection , fever ≥ 38.0 degree Celsius ( 100.5 degree Fahrenheit ) 13 . Known suspected infection human immunodeficiency virus ( HIV ) 14 . Evidence active hepatitis B ( HBV ) hepatitis C virus ( HCV ) 15 . Evidence active latent tuberculosis 16 . Vaccination live virus within 12 week enrollment randomization plan live virus vaccination continue week 52 study . Vaccination antigen kill organism must give within 12 week plan within 8 week dose cycle . 17 . Any infectious mononucleosislike illness within 6 month enrollment randomization 18 . Serologic clinical evidence acute infection EpsteinBarr virus ( EBV ) 19 . Serologic evidence acute infection cytomegalovirus ( CMV )</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Double Blind</keyword>
	<keyword>Parallel Group</keyword>
	<keyword>Controlled Clinical Trial</keyword>
</DOC>